Breast Cancer Treatment | AROMASIN® (exemestane tablets
Important Safety Information AND INDICATION. Do not take AROMASIN if you are allergic to AROMASIN or to anything in it. The active ingredient is exemestane
Aromasin Oral : Uses, Side Effects, Interactions, Pictures
This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also
Side Effects of Aromasin (Exemestane), Warnings, Uses - RxList
Cunha, DO, FACOEP. Last reviewed on RxList 6/06/2018. Aromasin (exemestane) is an antineoplastic (anticancer) agent used to treat breast cancer in postmenopausal women. Aromasin is often given to women whose cancer has progressed even after taking tamoxifen (Nolvadex, Soltamox) for 2 to 3 years
Exemestane (Aromasin) - Breast Cancer Now
Exemestane is a drug used to treat breast cancer in women who have gone through the menopause. You may also hear it called Aromasin, which is its best-known
Aromasin
Mar 28, 2020 - Aromasin (chemical name: exemestane) is an aromatase inhibitor approved by the U.S. Food and Drug Administration (FDA) to treat:
Aromasin - Drug Information - Chemocare
Aromasin (Exemestane) hormone therapy side effects, how it's given, how it works, precautions and self care tips in treatment of breast cancer
Exemestane (Aromasin) | Cancer information | Cancer
Exemestane is a type of hormone therapy drug. It is also known by its brand name Aromasin. You might have it as a treatment for breast cancer after you have had
Aromasin (exemestane) dosing, indications, interactions
Medscape - Indication-specific dosing for Aromasin (exemestane), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy
Exemestane (Aromasin®) | OncoLink
May 21, 2019 - Exemestane is an aromatase inactivator, which works to decrease the overall levels of estrogen in a woman's body. In women who have gone
Aromasin (Exemestane): Uses, Dosage, Side Effects ... - RxList
AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three